Groowe Groowe BETA / Newsroom
⏱ News is delayed by 15 minutes. Sign in for real-time access. Sign in

Human Plasma Like Medium Market Global Report 2026 | Capitalize on 8.6% CAGR as Thermo Fisher Scientific, Sartorius, Sigma Aldrich and HiMedia Advance IVD and Gene Therapy

globenewswire.com
TMO Thermo Fisher Scientific is mentioned as a company advancing the IVD and Gene Therapy markets, which are key growth drivers for human plasma-like medium. The article does not provide specific sentiment towards Thermo Fisher Scientific itself but places it within a growing market.

Human Plasma Like Medium Market Global Report 2026 | Capitalize on 8.6% CAGR as Thermo Fisher Scientific, Sartorius, Sigma Aldrich and HiMedia Advance IVD and Gene Therapy Dublin, Oct. 21, 2026 (GLOBE NEWSWIRE) -- "Human Plasma Like Medium Market Report 2026" has been added to ResearchAndMarkets.com's offering.

The global human plasma-like medium market is experiencing strong growth as biomedical research organizations, biopharmaceutical companies, and healthcare laboratories seek more physiologically relevant cell culture environments. The market is projected to increase from $0.91 billion in 2025 to $0.99 billion in 2026, representing a compound annual growth rate (CAGR) of 8.9%. Growth has been supported by increased biomedical research activity, expanding plasma-processing capabilities, rising healthcare expenditure, and greater demand for advanced culture media across drug discovery and therapeutic development.

By 2030, the human plasma-like medium market is expected to reach $1.38 billion, expanding at a CAGR of 8.6% from 2026. Key market growth drivers include the rising incidence of chronic, infectious, and immunodeficiency diseases; increasing investment in biologics; continued expansion of precision medicine; and wider adoption of advanced research products in emerging economies. Technological advances in medium formulation, contamination control, digital laboratory systems, and scalable manufacturing are also expected to improve product consistency and accelerate market development.

Growing demand for in-vitro diagnostics is a major factor supporting the human plasma-like medium market. An aging global population and the increasing prevalence of chronic and infectious diseases are creating a greater need for early diagnosis, routine screening, and continuous health monitoring. Human plasma-like media provide physiologically relevant conditions for disease modeling, assay validation, biomarker research, and therapeutic development, helping laboratories improve the accuracy and reproducibility of testing workflows.

Diagnostic activity continues to increase across major healthcare systems. According to NHS England, Community Diagnostic Centres conducted 2,328,300 diagnostic tests in 2024/25, compared with 1,498,000 in 2023/24. This 55.6% year-over-year increase demonstrates the expanding demand for diagnostic services and related laboratory technologies. As testing volumes rise, demand is expected to grow for advanced media that support dependable research, validation, and clinical development.

The expanding gene therapy sector is another important market driver. Advances in genetic sequencing and precision diagnostics are helping researchers identify disease-causing mutations and develop more targeted treatments. Human plasma-like medium supports gene therapy research by improving cell viability, growth, and functional performance during gene delivery, expression analysis, and treatment evaluation. These capabilities enable researchers to assess therapeutic candidates under conditions that more closely reflect human physiology.

Gene therapy approvals also indicate sustained momentum in advanced therapeutic development. According to the American Society of Gene & Cell Therapy, the US Food and Drug Administration approved six gene therapy products in 2023, compared with five in 2022. Continued progress in gene and cell therapy pipelines is expected to increase demand for reliable culture environments throughout preclinical research, process development, efficacy evaluation, and biomanufacturing.

Innovation in animal-free and scalable culture supplements is shaping the competitive direction of the human plasma-like medium market. Developers are prioritizing products that reduce biological variability, contamination risks, and reliance on animal-derived materials while maintaining strong cell growth and viability. In April 2025, PL Bioscience Inc. introduced an artificial human platelet lysate for cell culture applications. The product is designed to support translational research, regenerative medicine, and large-scale cell therapy manufacturing as an alternative to conventional platelet lysate and serum supplements.

Human plasma-like media are available in liquid and powder formats. Liquid products provide ready-to-use culture conditions, while powder formats can offer storage, transportation, and formulation advantages. Key applications include cell culture, drug discovery, regenerative medicine, disease modeling, toxicology research, assay development, and gene therapy studies. Major end users include academic institutions, biopharmaceutical companies, contract research organizations, hospitals, and laboratories. Products are distributed through direct sales, specialist distributors, and online platforms.

North America was the largest regional market for human plasma-like medium in 2025, supported by established biotechnology infrastructure, substantial research funding, advanced diagnostic capacity, and strong gene and cell therapy activity. Asia-Pacific is expected to be the fastest-growing region during the forecast period as investment in biomedical research, biomanufacturing, and healthcare infrastructure increases. The market covers Asia-Pacific, Southeast Asia, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa. Countries analyzed include Australia, Brazil, Canada, China, France, Germany, India, Indonesia, Italy, Japan, Russia, South Korea, Spain, Taiwan, the United Kingdom, and the United States.

Markets Covered:

1) By Product Type: Liquid; Powder

2) By Distribution Channel: Direct Sales; Distributors And Wholesalers; Online Platforms

3) By Application: Cell Culture; Drug Discovery; Regenerative Medicine; Other Applications

4) By End User: Academic And Research Institutes; Biopharmaceutical Companies; Contract Research Organizations; Hospitals And Diagnostic Laboratories; Other End-Users

Subsegments:

1) By Liquid: Cell Culture Medium; Growth Factor Supplements; Buffer Solutions; Additive Formulations; Stabilizers

2) By Powder: Lyophilized Cell Culture Medium; Protein Supplements; Mineral Blends; Vitamin Formulations; Reconstitution Agents

Time Series: Five years historic and ten years forecast.

Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita.

Data Segmentation: Country and regional historic and forecast data, market share of competitors, market segments.

Key Attributes

The companies featured in this Human Plasma Like Medium market report include:

For more information about this report visit https://www.researchandmarkets.com/r/608fu

About ResearchAndMarkets.com

ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.